Capricor Therapeutics (CAPR) stock gained as reports suggest a former executive could become the FDA's top gene therapy regulator. This potential leadership shift boosts approval prospects for its DMD therapy, Deramiocel, ahead of an August 22 decision. The FDA recently resumed review after requesting additional clinical data.